On Feb. 1, Vertex Pharmaceuticals (NASDAQ:VRTX) released its earnings for the fourth quarter ended Dec. 31.
- Vertex's hepatitis C drug, telaprevir, has shown good clinical trial results to date. Phase 3 trials are expected to start this year, with filing for Food and Drug Administration approval to follow in 2008.
- For the full year 2007, Vertex expects total revenue of $280 million to $320 million.
- Vertex expects research and development expenses of $560 million to $600 million for 2007, including $45 million of expenses for stock-based compensation.
(Figures in millions, except per-share data)
Income Statement Highlights
|
Q4 2006 |
Q4 2005 |
Change | |
|---|---|---|---|
|
Sales |
$94.3 |
$63.8 |
47.8% |
|
Net Profit |
($27.3) |
($38.1) |
N/A |
|
EPS |
($0.22) |
($0.38) |
N/A |
|
Diluted Shares |
123.9 |
100.5 |
23.3% |
Get back to basics with a look at the income statement.
Margin Checkup
|
Q4 2006 |
Q4 2005 |
Change* | |
|---|---|---|---|
|
Gross Margin |
96.6% |
95.6% |
1.0 |
|
Operating Margin |
(37.1%) |
(41.4%) |
4.3 |
|
Net Margin |
(29.0%) |
(59.8%) |
30.8 |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$761.8 |
$407.5 |
86.9% |
|
Accounts Rec. |
No data |
No data |
No data |
|
Inventory |
No data |
No data |
No data |
There was no data for liabilities.
Learn the ways of the balance sheet.
Cash Flow Highlights
A statement of cash flows wasn't provided.
Find out why Fools always follow the money.
Related companies:
- InterMune (NASDAQ:ITMN)
- OSI Pharmaceuticals (NASDAQ:OSIP)
- Cephalon (NASDAQ:CEPH)
- Sepracor (NASDAQ:SEPR)
- Schering-Plough (NYSE:SGP)
Related Foolishness:
- Vertex: Coming Together Nicely
- Vertex's Healthy Trial Results
- 2006 in Review: Vertex Pharmaceuticals
Vertex Pharmaceuticals and InterMune are Rule Breakers selections. InterMune is up 101% and Vertex is up 225% since the recommendations were made. See how the rest of the picks are doing with a free trial.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
